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Abstract
Background: AhR activates the transcription of several target genes including CYP1B1. Recently, we showed
CYP1B1 as the major cytochrome P450 (CYP) enzyme expressed in human brain microvessels. Here, we studied the
effect of AhR activation by environmental pollutants on the expression of Cyp1b1 in rat brain microvessels.
Methods: Expression of AhR and Cyp1b1 was detected in isolated rat brain microvessels. AhR was
immunovisualised in brain microvessel endothelial cells. The effect of AhR ligands on Cyp1b1 expression was
studied using isolated brain microvessels after ex vivo and/or in vivo exposure to TCDD, heavy hydrocarbons
containing diesel exhaust particles (DEP) or Δ9-tetrahydrocannabinol (Δ9-THC).
Results: After ex vivo exposure to TCDD (a highly potent AhR ligand) for 3 h, Cyp1b1 expression was significantly
increased by 2.3-fold in brain microvessels. A single i.p. dose of TCDD also increased Cyp1b1 transcripts (22-fold)
and Cyp1b1 protein (2-fold) in rat brain microvessels at 72 h after TCDD. Likewise, DEP treatment (in vivo and ex
vivo) strongly induced Cyp1b1 protein in brain microvessels. DEP-mediated Cyp1b1 induction was inhibited by
actinomycin D, cycloheximide, or by an AhR antagonist. In contrast, a sub-chronic in vivo treatment with Δ9-THC
once daily for 7 seven days had no effect on Cyp1b1 expression
Conclusions: Our results show that TCDD and DEP strongly induced Cyp1b1 in rat brain microvessels, likely
through AhR activation.
Keywords: Aryl hydrocarbon Receptor, Cyp1b1, TCDD, diesel exhaust particles, brain microvessels
Background
The blood-brain barrier (BBB) is a dynamic neurovascu-
lar unit composed of three main cell types: brain micro-
vessel endothelial cells sealed by tight junctions,
astrocyte end-foot processes ensheathing microvessels,
and pericytes sharing the basal membrane with endothe-
lial cells. Due to tight junctions limiting paracellular dif-
fusion and the presence of drug efflux transporters and
drug-metabolizing enzymes, the BBB is both a physical
and a metabolic barrier that selectively controls brain
penetration of xenobiotics. Recently, we showed that
CYP1B1, a cytochrome P450 (CYP) enzyme, was the
most highly expressed CYP gene in human brain micro-
vessels [1]. Expression of genes encoding CYP enzymes
is regulated in several peripheral tissues by transcription
factors such as the pregnane-X-receptor (PXR), the con-
stitutive androstane receptor (CAR), and the aryl hydro-
carbon receptor (AhR) [2]. AhR is a cytosolic ligand-
dependent transcription factor of the bHLH-PAS (basic
helix-loop-helix/Per-Arnt-Sim) superfamily. AhR is acti-
vated by binding of several classes of structurally differ-
ent aromatic compounds and environmental pollutants
such as polycyclic aromatic hydrocarbons (PAHs) and
halogenated aromatic hydrocarbons (HAHs) like 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD, dioxin) [3]. Briefly,
upon ligand binding in the cytosol, AhR translocates
into the nucleus where it heterodimerizes with its
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partner aryl hydrocarbon nuclear translocator (ARNT).
The AhR/ARNT complex activates in turn xenobiotic
response elements (XRE) in the promoter region of sev-
eral AhR target genes, thus increasing their transcription
[4,5]. AhR target genes include several genes encoding
CYP enzymes such as CYP1A1, CYP1A2 and CYP1B1
[6,7], as well as ATP-binding cassette (ABC) transporters
such as ABCG2 [8] and genes involved in cell cycle regu-
lation, cell proliferation, inflammation, and apoptosis
[9,10]. High levels of AhR mRNA were detected in
human brain microvessels and in the hCMEC/D3 human
cerebral microvascular endothelial cells, a promising in
vitro model of the human BBB [1,11]. Furthermore,
TCDD, the most potent AhR activator, highly induced
the expression of CYP1B1 and CYP1A1 in hCMEC/D3
cells [11]. Consistent with this, AhR agonists increased
Cyp1a1 and Cyp1b1 in many brain regions in rat and in
blood-brain interfaces of mice and rats [12,13]. TCDD
has also been shown to induce both Cyp1a1 and Cyp1b1
in cultured murine cerebral vascular endothelial cells and
astrocytes [14]. Regarding Cyp1b1, this enzyme has been
demonstrated to metabolise various endogenous com-
pounds like retinol, arachidonic acid, melatonin and
estrogens [7,15]. Moreover, Cyp1b1 also selectively bioac-
tivates various PAHs (benzo[a]pyrene, DMBA, anthra-
cenes) into intermediates that are DNA-reactive [16]. All
these studies suggest that AhR control the expression of
CYP1B1 at the BBB.
First, this work aimed to examine TCDD-mediated
activation of AhR on Cyp1b1 expression in vivo in rat
brain microvessels. In addition, we studied the effect of
two other potential AhR ligands: Δ9-tetrahydrocannabi-
nol (Δ9-THC) and diesel exhaust particles (DEP). Δ9-
THC, the psychoactive component of marijuana, has
been discussed as a potential AhR ligand due to its abil-
ity to induce Cyp1a1 expression in a murine hepatoma
cell line [17]. DEP are complex environmental toxicants
containing heavy hydrocarbons derived from fuel like
PAHs and HAHs that people are exposed to daily and
known to activate AhR [18,19].
Methods
Reagents and equipment
RNA extraction kits were purchased from Qiagen
GmbH (Hilden, Germany). RT-PCR reagents were pur-
chased from Invitrogen (Invitrogen, France). Primers
were synthesized by Invitrogen Life Technologies (Invi-
trogen, France). The LC Fast Start DNA Master SYBR
Green I kit was purchased from Roche Diagnostics
(Meylan, France), and the Power SYBR Green PCR Mas-
ter Mix was from Applied Biosystems (Foster City, CA,
USA). 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD,
dioxin, 50 μg/mL in DMSO) was obtained from LGC
Promochem (Molsheim, France) and Δ9-THC (27 mg/
mL in ethanol) was from Sigma-Aldrich (Saint Quentin
Fallavier, France). Antibodies and supplies used for wes-
tern blotting were: polyclonal rabbit anti-rat Cyp1a1,
polyclonal rabbit anti-Cyp1b1, monoclonal mouse anti-
AhR, and monoclonal mouse anti-b-actin antibodies
(Abcam, Cambridge, UK and Abcam, Cambridge, MA,
USA), horseradish peroxidase-conjugated monkey anti-
rabbit secondary antibody and horseradish peroxidase-
conjugated monkey anti-mouse secondary antibody
(Amersham, Buckinghamshire, UK), and Alexa Fluor®
488 goat anti-mouse IgG (H+L) antibody (Invitrogen,
Carlsbad, CA, USA). Proteins were detected using
SuperSignal® West Pico Chemoluminescent Substrate
(Pierce, Rockford, IL, USA). Diesel exhaust particles
(DEP) were obtained from NIST [20] (Gaithersburg,
MD, USA). Carbon black (CB) mock particles were a
kind gift from Degussa Corporation (Akron, OH, USA).
AhR antagonist (CH-223191) [21] and IgG control anti-
body were from Calbiochem-Novabiochem (La Jolla,
CA, USA). Protein A/G Beads were from Pierce (Rock-
ford, IL). Other chemicals and reagents were purchased
from Sigma-Aldrich (France and St. Louis, MO, USA)
or Invitrogen (Cergy-Pontoise, France). Equipments
used were: a nucleic acid spectrophotometer (Nanodrop
ND-1000, NanoDrop Technologies, USA), a program-
mable thermal cycler (PTC-100 programmable thermal
controller, MJ research Inc., USA), a Light Cycler ther-
mal cycler (Light-Cycler® instrument, Roche Diagnos-
tics), and a 7900 HT Real-Time PCR Detection System
(Applied Biosystems, Foster City, CA).
Animal treatments
All animal experiments were based on the same experi-
mental setup. For treatment with TCDD and Δ9-THC,
male Sprague-Dawley rats (230-250 g) were obtained
from Charles River (L’arbresle, France). For treatment
with DEP, male CD® IGS Sprague-Dawley rats (275-300
g) were obtained from Charles River (Portage, MI,
USA). Rats were housed in groups of four animals per
cage under standard 12:12-hour light/dark conditions
(light from 8:00 a.m. to 8 p.m.) in a temperature- and
humidity-controlled room. Animals had access to food
and water ad libitum. Before using rats for experiments,
they were allowed to adapt to the animal facility for 3-5
days.
The care and treatment of animals (TCDD and Δ9-
THC treatment) were in accordance with standards and
guidelines approved by the European Communities
Council Directive (86/609/EEC). Animal protocols were
approved by the Institutional Animal Care and Use
Committees of the EPA, RTP, NC, and the University of
Minnesota and were in accordance with AAALAC regu-
lations and the Guides to Animal Use of the University
of Minnesota and NIH animal guidelines.
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For in vivo TCDD exposure, animals were dosed with
a single i.p of TCDD (25 μg/kg body weight) or control
(1:9 DMSO: Corn Oil) and sacrificed 72 h after the
TCDD or control injection as previously described
[22,23].
For in vivo Δ9-THC exposure, Δ9-THC (10 mg/kg
body weight) or control (1:1:18 ethanol: cremophor: sal-
ine) were administered i.p once daily for 7 days. This in
vivo dosing protocol was chosen for several reasons: (1)
Δ9-THC has a half-life of about 25-36 h, which is long
enough for a once daily administration, (2) Δ9-THC is
likely a less potent AhR activator compared to TCDD,
(3) the 7-day Δ9-THC dosing scheme is currently used
in our laboratory, and we observed that it causes an
addiction-like behavioral effect (unpublished data). Rats
were sacrificed 12 h after the last Δ9-THC or control
injection.
For in vivo DEP exposure, diesel engine exhaust was
generated by operating a 30-kW (40 hp) four-cylinder
indirect injection Deutz diesel engine (BF4M1008) and
was collected as previously described [24]. Rats in inha-
lation chambers were exposed to 0.5 mg/m3 and 2 mg/
m3 of this diesel engine exhaust for 5 h/day, 5 days/
week for 4 consecutive weeks. Inhalation fumes con-
tained diesel exhaust engine gas as well as diesel exhaust
particulate matter. These DEP inhalation doses have
been used in previous studies and are based on DEP
concentrations found in ambient air during heavy traffic
[25,26].
Preparation of DEP working suspension
DEP working suspension using diesel exhaust particles
(SRM 2975) that were derived from diesel-powered fork-
lifts was prepared as previously described [27]. Briefly, 2
mg of DEP was suspended in 10 mL PBS buffer, vor-
texed, and sonicated for 30 min at 25°C using an ultra-
sonic processor (Bransonic®, Model 3510, Branson
Ultrasonic Cooperation, Danbury, CT, USA). The sus-
pension was filtered through a 0.22-μm filter (MillexGS;
Millipore, Billerica, MA, USA).
Isolation of rat brain microvessels
All steps in the isolation of brain microvessels were car-
ried out at 4°C. Rats treated with TCDD, Δ9-THC or
DEP were anesthetized with isoflurane and sacrificed by
decapitation after the last injection or euthanized by
CO2 inhalation and decapitated. Brains were immedi-
ately removed and placed in ice-cold HBSS. Cerebella,
meninges, brainstems, and large superficial blood vessels
were removed. Rat cortex microvessels were isolated
according to a protocol that results in the lowest con-
tamination with astrocyte and neuron mRNA and the
highest yield of endothelial cells mRNA [28]. Isolated
brain microvessels were also free from red blood cells,
other contaminating cells such as microglia, and cell
debris [27]. Briefly, cortices were minced and homoge-
nized with a Potter-Thomas homogenizer (Konte Glass,
Vineland, NJ, USA). The resulting homogenate was cen-
trifuged at 1000 g for 10 min, and the microvessel-
enriched pellet was suspended in 17.5% dextran and
centrifuged for 15 min at 4400 g at 4°C in a swinging
bucket rotor. The resulting pellet was suspended in
HBSS containing 1% BSA, while the supernatant con-
taining a layer of myelin was centrifuged once more.
The resulting microvessel suspension was passed
through a 100 μm nylon mesh, and the filtrate was then
passed through a 20 μm nylon mesh. Microvessels
retained by the nylon 20 μm mesh were immediately
collected and used for experiments or frozen at -80°C.
For ex vivo experiments, freshly isolated brain micro-
vessels from naïve rats were incubated with different
concentrations of either TCDD (25 nM) or DEP (0, 5,
50, 200 μg/mL) as previously described [27].
RNA extraction and reverse transcription
Total RNA was extracted from tissues and organs of
each rat. Total RNA from isolated brain microvessels
was obtained by lysing the surrounding basal lamina
with proteinase K and then extracting total RNA using
the RNeasy Fibrous Tissue Micro kit according to the
manufacturer’s instructions. RNA samples were purified
from contaminating genomic DNA by treatment with
DNase (RNase-Free DNase Set, Qiagen SA). RNA con-
centration and purity were assessed spectrophotometri-
cally at 260 nm using a Nanodrop® spectrophotometer;
RNA integrity was assessed by electrophoresis on a 0.8%
agarose gel. One μg of total RNA was reverse tran-
scribed into cDNA in a final volume of 20 μL. The mix-
ture consisted of 1 μg total RNA, 500 μM of each
dNTP, 10 mM DTT, 1.5 μM random hexa-nucleotide
primers, 20 U RNAse in ribonuclease inhibitor, and 100
U SuperScript II reverse transcriptase. Hexamers were
annealed at 25°C for 10 min, products were extended at
42°C for 30 min, and the reaction was terminated by
heating to 99°C for 5 min before being quick-chilled to
4°C and stored at -80°C.
Non-quantitative and quantitative RT-PCR (q-PCR)
RT-PCR for AhR and Cyp1b1 was performed with Taq
DNA Polymerase from Promega (Madison, WI, USA)
using primers for rat AhR and Cyp1b1 (Table 1) that
were custom-synthesized by Qiagen Operon (Alameda,
CA, USA). PCR products were resolved on a 2% agarose
gel at 100 V for 75 min.
The effect of Δ9-THC and TCDD on the expression of
Cyp1a1 and Cyp1b1 was investigated by quantitative
real-time PCR (q-PCR). ß-actin was used as an endogen-
ous reference for normalizing target gene mRNA. Gene
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expression was evaluated by q-PCR as previously
described [28]. Primers were designed using OLIGO
6.42 software (Medprobe, Norway) (Table 1). PCR reac-
tions were performed on a Light-Cycler® instrument
using the LC-FastStart DNA Master SYBR Green I kit.
cDNAs from either control or treated rats were used to
generate external calibration standards for each gene.
The PCR reaction mixture consisted of 1 μL LC-Fas-
tStart DNA Master SYBR Green mix, 1.2 μL of 10 mM
MgCl2, 0.5 μL of each upper and lower primer (final
concentration 0.5 μM), and 1.8 μL water. The cDNAs
were diluted 40-fold, and 5 μL aliquots were mixed with
an equal volume of PCR mixture to yield a final volume
of 10 μL. The thermal cycling conditions were 8 min at
95°C followed by 40 amplification cycles at 95°C for 5 s,
64°C for 5 s, and 72°C for 5 s. A target gene was consid-
ered to be easily quantifiable when the Ct that was
obtained for the less diluted cDNA (1/20) sample was
lower than 30. A Ct value of 32 was set as the detection
limit. A calibration curve using serial dilutions of cDNA
standard was used to determine the relative expression
of Cyp1a1 and Cyp1b1 genes in control (vehicle) and
TCDD-treated rat (n = 8 rats per group) and in control
(vehicle) and Δ9-THC-treated rat (n = 12 rats per
group). The (fold) change was expressed by the ratio
(gene of interest/ß-actin)treated/(gene of interest/ß-actin)
control.
Immunofluorescence
Freshly isolated brain microvessels were transferred to
glass cover slips and fixed for 15 min with 3% parafor-
maldehyde/0.2% glutaraldehyde at room temperature.
After washing with PBS, microvessels were permeabi-
lised for 20 min with 1% (v/v) Triton X-100 in PBS and
subsequently blocked with 1% BSA in PBS. Microvessels
were incubated overnight at 4°C with the primary anti-
body to AhR (1:100). After washing with 1% BSA,
microvessels were incubated for 1 h at 37°C with Alexa
Fluor® 488-conjugated secondary IgG (1:500, 4 μg/mL;
Invitrogen, Eugene, OR, USA); negative controls were
incubated with secondary antibody only. Nuclei were
counterstained in blue with 2.5 μg/mL DAPI for 15 min.
AhR staining was visualised in green using confocal
microscopy (Nikon C1 LSC microscope unit, Nikon
TE2000 inverted microscope, 40x oil immersion objec-
tive, NA 1.3, 488 nm line of an argon laser, 402 nm line
of a solid state UV laser; Nikon Instruments Inc., Mel-
ville, NY, USA).
Immunoprecipitation
Isolated brain microvessels were homogenized in lysis
buffer (Sigma, St. Louis, MO, USA) containing Com-
plete® protease inhibitor (Roche, Mannheim, Germany).
The lysate was cleared by centrifugation at 10 000 g for
15 min at 4°C. Identical amounts of pre-cleared micro-
vessel lysates (50 μg of protein) were immunoprecipi-
tated with 5 μg AhR antibody, 5 μg IgG antibody (IgG
control), or antibody-free PBS buffer (negative control)
by overnight incubation at 4°C. The immune complexes
were precipitated with Protein A/G beads (Pierce, Rock-
ford, IL, USA) and washed 3 times with RIPA buffer
(Sigma, Dedham, MA, USA) and once with PBS. Immu-
noprecipitated proteins were eluted with LDS buffer
(Invitrogen, Carlsbad, CA, USA) and analyzed by wes-
tern blotting.
Western blotting analysis
For Cyp1b1, Cyp1a1, and AhR western blots, brain
microvessels were homogenized in lysis buffer (Sigma,
St. Louis, MO, USA) containing Complete® protease
inhibitor (Roche, Mannheim, Germany) and centrifuged
at 10 000 g for 15 min. Denucleated supernatants were
used as microvessel lysates, and protein concentrations
were determined. Western blots were performed using
the Invitrogen NuPage™ Bis-Tris electrophoresis and
blotting system (Invitrogen, Carlsbad, CA, USA). After
protein transfer, blotting membranes were blocked and
incubated with primary antibody (AhR 1:100, Cyp1b1
1:500 (1 μg/mL), Cyp1a1 1:1000, b-actin 1:1000 (1 μg/
mL)). Membranes were washed and incubated with
horseradish peroxidase-conjugated ImmunoPure® sec-
ondary IgG (1:15,000; Pierce, Rockford, IL, USA) for 1
h. Proteins were detected using SuperSignal® West Pico
Chemoluminescent Substrate (Pierce, Rockford, IL,
USA), and bands were visualised and recorded using a
BioRad Gel Doc 2000™ gel documentation system
Table 1 Sequences of primers used for RT-PCR and q-PCR
Gene Forward primer (5’-3’) Reverse Primer (5’-3’) Length (bp) GenBank accession*
b-Actin CTGGCCCGGACCTGACAGA GCGGCAGTGGCCATCTCTC 132 NM_031144
AhRa CTCCCTCCACAGTTGGCTTTGTTTG GATTCTGCGCAGTGAAGCATGTCAG 233 NM_013149
Cyp1a1 AACCCACACCTGTCACTGA CTGGTGAAACAGGGGGAT 132 NM_012540
Cyp1b1 GCTTGCCAGTGAGAGAGG TTCTCAAGAATGAGCGGAA 135 NM_012940
Cyp1b1a GCAGATCAACCGCAACTTCAGCAAC GTCTGTAATAGTGGCAGGCACATCC 193 NM_012940
a for RT-PCR
* http://www.ncbi.nlm.nih.gov/
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(BioRad, Hercules, CA, USA). Rat Cyp1a1 supersomes™
and Cyp1b1 microsomes were supplied by BD Bios-
ciences (Woburn, MA, USA) and used as positive con-
trols for Cyp1a1 and Cyp1b1, respectively.
Statistical analysis
Statistical analyses were done with GraphPad Prism® 4.0
software (GraphPad Software Inc., San Diego, CA,
USA). Data for qPCR are expressed as means ± SD. Stu-
dent’s unpaired t-tests were performed to identify signif-
icant differences between rats treated with TCDD or
Δ9-THC and control-treated rats. All the tests were
two-tailed and statistical significance was set at p < 0.05.
Data received from optical density measurements from
western blots are means ± SEM.
Results
AhR expression in different rat tissues and its localization
in isolated rat brain microvessels
AhR transcripts (233 bp amplicon) were detected in
total brain, brain microvessels, choroid plexus and per-
ipheral tissues (Figure 1A). AhR protein was also
Figure 1 AhR expression in different rat tissues and AhR immunolocalization in isolated rat brain microvessels. (A) RT-PCR of liver,
kidney, choroid plexus, total brain, and rat brain microvessels for rat AhR. The RT-PCR shows a signal for AhR mRNA at 233 bp. (B) Western blot
of immunoprecipitated AhR from rat brain microvessels. (C) Representative image of a brain microvessel immunostained for AhR (green); nuclei
were counterstained with DAPI (blue).
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detected after immunoprecipitation and western blotting
in brain microvessels, which showed a strong signal for
AhR (Figure 1B). Importantly, immunoprecipitations
without AhR antibody (negative control) or using an
IgG control antibody (IgG control) instead of anti-AhR
antibody showed no band demonstrating the specificity
of the AhR signal. Using immunostaining we localised
AhR in the cytoplasm of brain microvessel endothelial
cells (Figure 1C), which is consistent with the location
of this transcription factor [9,10]. Thus, AhR is
expressed at both the mRNA and protein levels in rat
brain microvessels.
Effect of TCDD and Δ9-THC on CYP expression in isolated
brain microvessels
To demonstrate expression of Cyp1b1, we first performed
both RT-PCR and western blotting. High levels of Cyp1b1
transcript (193 bp amplicon, Figure 2A) and protein were
detected in brain microvessels, total brain, liver, choroid
plexus and kidney (Figure 2B). The apparent molecular
weight of Cyp1b1 protein was determined by digital analy-
sis to be 62 kDa, a value that is consistent with the calcu-
lated molecular weight of Cyp1b1 at 60.5 kDa.
To test if AhR induces Cyp1a1 and Cyp1b1 genes in
isolated brain microvessels, we first incubated ex vivo
brain microvessels from naïve rats with 25 nM TCDD, a
highly potent AhR ligand, and determined the expres-
sion of Cyp1b1 and Cyp1a1, two well-known AhR target
genes. In control brain microvessels, Cyp1a1 mRNA was
about 60-fold less abundant than that of Cyp1b1.
Cyp1b1 and Cyp1a1 mRNA expression levels in brain
microvessels were significantly increased by 2.5-fold and
11-fold as early as 3 h after ex vivo TCDD exposure,
respectively (Figure 3A).
To test the effect of TCDD on Cyp1a1 and Cyp1b1 in
vivo, we dosed animals with TCDD (one dose of 25 μg/kg
i.p.) and measured Cyp1a1 and Cyp1b1 transcript levels in
isolated brain microvessels with q-PCR at 72 h after
TCDD administration. TCDD substantially increased
Cyp1b1 and Cyp1a1 mRNA levels in isolated brain micro-
vessels by 22-fold and 260-fold, respectively (Figure 3B). In
some vehicle-treated samples, Cyp1a1 transcripts were not
detectable and relative expression was therefore calculated
using the lowest standard calibration curve.
Δ9-THC has been discussed as a potential AhR ligand
due to its ability to induce Cyp1a1 expression in a mur-
ine hepatoma cell line [17]. Therefore, we studied
whether sub-chronic treatment with Δ9-THC induces
Cyp1b1 and Cyp1a1 in rat brain microvessels. Impor-
tantly, Δ9-THC did not change Cyp1b1 expression (1.0
± 0.12 in untreated rats versus 1.1 ± 0.18 in Δ9-THC-
treated rats, n = 12 per group, data not shown). Cyp1a1
transcripts were not quantified in brain microvessels
from control- and Δ9-THC-treated rats.
Since TCDD strongly increased mRNA expression of
Cyp1b1 and Cyp1a1 in isolated brain microvessels, we
measured Cyp1a1 protein levels 72 h after TCDD
administration. Cyp1a1 protein was not detected in
either TCDD-treated or untreated rats. However,
Cyp1a1 was present in rat supersomes™ (positive con-
trol) at the correct molecular weight (59 kDa; Figure 4).
In contrast, 12 h (Figure 5A) and 72 h (Figure 5B) after
TCDD dosing, Cyp1b1 expression was increased by 80
± 13% and 100 ± 8% (SEM) respectively in TCDD-trea-
ted rats compared to control rats.
Effect of DEP exposure on Cyp1b1 expression in isolated
rat brain microvessels
Since Cyp1a1 was not detected at the protein level after
TCDD exposure, we focused on AhR-dependent regula-
tion of Cyp1b1 in the following studies. Diesel exhaust
particles (DEP) are a real environmental toxicant that
billions of people are exposed to on a daily basis [18].
Once inhaled, DEP can enter the circulation and trans-
locate to tissues throughout the body. Through this
route, DEP can reach the brain microvasculature and
studies showed that DEP even enter the brain [29-31].
DEP consist of a carbon core with adsorbed organic
chemicals such as PAHs and HAHs that are known
AhR activators [18,19]. Thus, in addition to the DEP
itself, the AhR-activating chemicals that are adsorbed to
the carbon core also enter the blood-stream and reach
the blood-brain barrier where they affect expression of
Figure 2 Gene and protein expression of Cyp1b1 in different
rat tissues. (A) RT-PCR of Cyp1b1 transcript levels in liver, kidney,
choroid plexus, total brain, and isolated brain microvessels. A signal
was detected at 193 bp. (B) Western blot showing Cyp1b1 protein
expression at 62 kDa.
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proteins [27]. Here we show that exposing rat brain
microvessels to DEP for 6 h ex vivo increased Cyp1b1
protein in a concentration-dependent manner up to 310
± 16% (SEM) of controls at 200 μg/ml DEP (Figure 6A;
data are means from 6 densitometric measurements;
brain capillaries used for western blots were pooled
from 10 rats). In contrast, carbon black mock particles
that are used as a negative control for particulate matter
did not cause such an increase in Cyp1b1 protein in
brain microvessels (Figure 6B). Note that the difference
in band intensities for the controls in Figures 6A and 6B
is not due to different expression levels, but to different
exposure times. Figure 6C shows that Cyp1b1 protein
expression was also significantly increased in brain
microvessels from rats that were exposed to 0.5 and 2
mg/m3 diesel engine exhaust containing DEP for 5 h/
day, 5 days/week for 4 consecutive weeks (0.5 mg/m3:
447 ± 26%, 2 mg/m3: 538 ± 40% of controls; data are
means ± SEM from 5 densitometric measurements;
brain capillaries used for western blots were pooled
from 6 rats per treatment group). Note that these DEP
doses are based on DEP concentrations found in ambi-
ent air during heavy traffic [25,26].
We also addressed the mechanism of DEP-mediated
Cyp1b1 induction in rat brain microvessels. Inhibiting
transcription with actinomycin D or inhibiting protein
synthesis with cycloheximide (CHX) abolished DEP-
mediated upregulation of Cyp1b1 protein expression in
isolated rat brain microvessels (Figures 7A and 7B).
Importantly, the use of the AhR antagonist CH-223191
blocked this DEP-mediated Cyp1b1 induction in brain
microvessels (Figure 7C), indicating that this effect is
AhR-dependent. Thus, these data demonstrate that
DEP induces Cyp1b1 in brain microvessels ex vivo and
in vivo and that this effect is likely to be AhR-
dependent.
Figure 3 Effect of TCDD on Cyp1a1 and Cyp1b1 mRNA levels in isolated rat brain microvessels. (A) Freshly isolated rat brain microvessels
from naïve rats were incubated ex vivo for 3 h with 25 nM TCDD (n = 4 rats per group). (B) Rats were dosed with a single i.p. dose of 25 μg/kg
TCDD and brain microvessels were isolated at 72 h (n = 8 rats per group). Data are shown as relative expression of Cyp1a1 or Cyp1b1 mRNA in
treated and control rats using q-PCR. Results are expressed as means ± SD ***p < 0.001 (Student’s t-test).
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Discussion
In peripheral tissues such as liver, CYP enzymes are
regulated by the same transcription factors including
PXR, CAR and AhR [2]. However, few studies exist on
the regulatory pathways of these enzymes at the BBB.
Recently, we demonstrated that AhR transcripts are
abundant in human brain microvessels [1] and that
TCDD, the highly potent AhR ligand, strongly upregu-
lated CYP1A1 and CYP1B1 in hMEC/D3 cells, a promis-
ing in vitro model of the human BBB [11]. Based on
these findings, we tested if AhR pathway is involved in
vivo in the regulation of Cyp1b1 in rat brain
microvessels. The present results show for the first time,
AhR expression and immunostaining in rat brain micro-
vessels in addition to Cyp1b1 upregulation after in vivo
and ex vivo exposure to well-known AhR ligands:
TCDD and heavy hydrocarbons-containing DEP. In this
Figure 4 Cyp1a1 protein expression in brain microvessels of
TCDD-treated rats. Rats were dosed with a single dose of TCDD
(25 μg/kg i.p.) and brain microvessels were isolated after 72 h for
Cyp1a1 analysis by Western blotting; rat Cyp1a1 supersomes were
used as positive control for Cyp1a1 expression.
Figure 5 Cyp1b1 protein expression in brain microvessels of
TCDD-treated rats. Rats were administered a single dose of TCDD
(25 μg/kg i.p.), and brain microvessels were isolated 12 h (A) and 72
h (B) after dosing. Rat microsomes were used as positive control for
Cyp1b1 expression. The amount of Cyp1b1 in each sample was
measured by densitometric analysis and normalized to b-actin.
Figure 6 Effect of DEP exposure on Cyp1b1 expression in
isolated rat brain microvessels. Western blots showing Cyp1b1
protein expression; b-actin was used as loading control. (A) Ex vivo
DEP exposure of brain microvessels increased Cyp1b1 in a
concentration-dependent manner. (B) Carbon black particles were
used as a negative control for particulate matter and did not have
any effect on Cyp1b1 protein levels in brain microvessels. (C)
Cyp1b1 protein expression was increased in brain microvessels from
rats that were exposed in vivo to 0.5 and 2 mg/m3 diesel engine
exhaust containing DEP for 5 h/day, 5 days/week for 4 consecutive
weeks. Brain capillaries were pooled from 6 rats per treatment
group.
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way, rat brain microvessels are a critical target of AhR
environmental pollutant ligands.
We first focused on AhR expression and localisation
in isolated rat brain microvessels. AhR was highly
expressed at both mRNA and protein level in rat brain
microvessels. These findings are in accordance with the
study of Filbrandt et al. showing that isolated murine
cerebral vascular endothelial cells express abundant level
of AhR protein [14]. By immunostaining, we localised
AhR protein within the cytoplasm of rat brain microves-
sel endothelial cells corresponding to the predominant
distribution of inactive (not ligand-bound) AhR [9].
Regarding Cyp1b1, expression of this enzyme at the
BBB is controversial. Cyp1b1 was not detected at the
mouse BBB but was immunolocalised in other BBB
interfaces like the leptomeninges [12]. Furthermore,
basal protein expression was undetected in primary
murine vascular endothelial cells [14] whereas CYP1B1
has been localised in human brain capillaries by immu-
nohistochemistry [32]. Here we found that Cyp1b1 is
constitutively expressed in different extrahepatic rat tis-
sues including brain and especially in brain microvessels.
Our western blot analysis of Cyp1b1 expression showed
that the apparent molecular weight slightly differed
depending on tissue samples suggesting that transcrip-
tional and/or post-transcriptional/translational events
might affect Cyp1b1 molecular weight. To our knowl-
edge, alternatively Cyp1b1 spliced variants have not
been described in the literature in contrast to Cyp1a1
ones reported in human brain [33].
Thus, like in human BBB, rat brain microvessels
express both Cyp1b1 and AhR, being therefore a suita-
ble model to assess AhR regulation pathway in vivo at
this interface.
We then studied TCDD effect on AhR-target gene
Cyp1b1 expression in rat brain microvessels. Here, we
report that Cyp1b1 was strongly induced by TCDD as
early as 3 h after exposing ex vivo rat brain microvessels
to 25 nM TCDD. In in vivo experiments, TCDD
induced an early and sustained upregulation of Cyp1b1
protein expression in rat brain microvessels. In fact
Cyp1b1 protein expression induction occurred at 12 h
post-injection and was maintained throughout 72 h.
Our results are consistent with a very recent study
showing that acute TCDD treatment upregulates
Cyp1b1 at the rat BBB 48 hours post-injection [34]. In
our study, in vivo Cyp1b1 induction happened earlier
(12 h after TCDD single dose) allowing less time for
potential indirect mechanisms to occur.
TCDD also induced Cyp1a1 expression at the mRNA
level ex vivo and in vivo. Despite high induction, we
could not detect Cyp1a1 protein in isolated brain micro-
vessels from control or TCDD-treated rats. By qPCR we
found in brain microvessels from naïve rats substantially
lower Cyp1a1 mRNA levels compared to Cyp1b1
mRNA levels (60-fold difference). Thus, Cyp1a1 mRNA
is barely detectable, which is consistent with findings in
human brain microvessels [1]. Consequently, Cyp1a1
protein was also undetectable in rat brain microvessels.
However, Wang et al. recently detected Cyp1a1 pro-
tein expression in isolated rat brain microvessels which
was increased by TCDD [34]. This suggests that discre-
pancies between studies may come from different tech-
nical approaches. However, using ultracentrifugation
Wang et al. isolated brain microvessel crude membranes
that include those of the endoplasmic reticulum where
Cyp1a1 is localised, thus allowing Cyp1a1 enrichment
and subsequent detection by Western blotting.
Δ9-THC has been reported to increase Cyp1a1 mRNA
in murine Hepa-1 cells through AhR pathway [17]. In
the present study, we did not observe induction in
Cyp1a1 and Cyp1b1 expression in rat brain microvessels
after sub-chronic Δ9-THC treatment, which is consistent
with our previous results showing an absence of
CYP1A1 and CYP1B1 induction after Δ9-THC exposure
of the human cerebral endothelial cell line hCMEC/D3
[11]. This discrepancy with experiment of Roth et al.
[17], may be due to inter-species differences or to a dif-
ference in the dosing range. Indeed, pharmacokinetic
studies showed that after sub-chronic Δ9-THC
Figure 7 DEP-mediated Cyp1b1 upregulation involves AhR.
Western blots showing Cyp1b1 protein expression; b-actin was used
as loading control. DEP-mediated upregulation of Cyp1b1 protein
expression in isolated rat brain microvessels is blocked with (A)
actinomycin D, an inhibitor of transcription, (B) cycloheximide (CHX),
an inhibitor of protein synthesis, and (C) an AhR antagonist (CH-
223191).
Jacob et al. Fluids and Barriers of the CNS 2011, 8:23
http://www.fluidsbarrierscns.com/content/8/1/23
Page 9 of 12
treatment of rats, plasma concentrations of Δ9-THC
were in the 2-4 ng/mL range [35], which is close to
those plasma concentrations observed in humans canna-
bis abuser [36] and about three orders of magnitude
lower than the Δ9-THC concentrations needed to
induce Cyp1a1 in vitro [17]. Through marijuana con-
sumption, users are exposed to psychoactive cannabi-
noids and also to toxicant-containing tar such as PAHs
[37]. These AhR ligands have been reported to occur at
higher levels in marijuana than in tobacco-tar [38].
Thus, even if Δ9-THC does not activate AhR in rats in
vivo, PAHs-containing marijuana tar could activate AhR.
Given the widespread use of marijuana around the
world, further experiments are needed to assess poten-
tial AhR activation by marijuana tar at the BBB.
DEP are complex environmental toxicants consisting
of a central core of elemental carbon and adsorbed
organic compounds such as PAHs and HAHs [18,19].
Here we observed that a chronic inhalation exposure to
DEP strongly upregulated Cyp1b1 expression in vivo in
rat brain microvessels. Ex vivo, DEP also induced
Cyp1b1 expression in rat brain microvessels. Further-
more, this effect was abolished by blocking transcription
or translation or by using an AhR antagonist, strongly
suggesting that DEP-mediated Cyp1b1 upregulation is
triggered by AhR activation.
AhR involvement in toxicological responses and carci-
nogenesis has been widely studied in the last decades.
However, increasing evidence suggests that AhR is not
only a cellular sensor of environmental pollutants but also
a key regulator of physiological functions. In fact, AhR is
involved in reproduction, immunity, and a wide variety of
basic cellular processes including proliferation, migration,
adhesion, and differentiation [9,10]. In addition, AhR-/-
mice display abnormal vascular structures in kidney, liver,
and eyes, which suggests that AhR is involved in vascular
development [39]. Recently, the highly potent AhR ligand
TCDD has been shown to decrease cerebral blood flow
and alter brain vessel morphology in developing zebrafish,
suggesting that TCDD through AhR activation may alter
brain vascular physiology [40]. Regarding the physiological
function of the Cyp1b1 enzyme, Cyp1b1-/- mice exhibit no
apparent abnormalities except in their anterior eye seg-
ment similar to what has been reported for patients with
primary congenital glaucoma [15]. Interestingly, primary
cultured retinal endothelial cells from Cyp1b1-/- mice lose
their ability to undergo capillary morphogenesis [41], sug-
gesting that Cyp1b1 is involved in angiogenesis. Further-
more, Cyp1b1 metabolises several endogenous
compounds like retinol, estrogens, and arachidonic acid
[7], which is turned into epoxyeicosatrienoic acid that has
vasodilatatory properties [42]. Interestingly, 17-b-estradiol,
a substrate of CYP1B1, increased the expression of vasoac-
tive factors in HUVEC [43]. Taken together, these data
indicate that both AhR and Cyp1b1 could be key elements
in the development and/or maintenance of a functional
BBB.
Besides, Cyp1b1 is known to bioactivate procarcino-
gens such as PAHs into more reactive metabolites so
that its induction may alter the BBB [16]. Through acti-
vating AhR, PAHs induce CYP1B1 expression and in
turn promote their own activation into carcinogens.
Therefore, DEP induction of CYP1B1 at the BBB may
bioactivate PAHs adsorbed to DEP into genotoxic inter-
mediates [44,45] that could increase levels of potentially
harmful chemicals, which may initiate BBB dysfunction
and/or brain disease.
Conclusion
The present study has shown Cyp1b1 upregulation by
environmental pollutants TCDD and DEP in vivo in rat
brain microvessels. Since BBB is likely to be a target of
AhR environmental pollutant ligands, further experi-
ments are required to assess the role AhR/Cyp1b1 play
at the BBB, especially with regard to their impact in tox-
icological and/or pathophysiological processes. It will
therefore be critical to explore whether the AhR/Cyp1b1
in the brain microvessel endothelium is beneficial or
harmful to BBB function.
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